Addyi Cost in Illinois 2026: Price, Insurance, Medicaid, and Compounded Options

What Does Addyi Actually Cost in Illinois in 2026?

Branded Addyi carries a manufacturer list price of $880 per month in Illinois in 2026, identical to the national wholesale acquisition cost set by Sprout Pharmaceuticals. Cash-paying patients who skip their insurance entirely will pay close to that figure at most Illinois retail pharmacies. A 30-tablet supply (one tablet per night) represents the standard dispensing unit, and no generic flibanserin tablet has received FDA approval as of mid-2025, so that list price faces no direct generic competition at retail.

The $880 figure is a sticker price, not what most patients pay. Insurance coverage, manufacturer savings programs, and compounded alternatives each create meaningful price breaks, discussed in the sections below. Patients should always run the Sprout savings card and their insurance plan together before paying cash, because the interaction between the two can drop the effective monthly cost to zero for some commercially insured Illinois residents.

The FDA approved Addyi (flibanserin 100 mg) on August 18, 2015, making it the first pharmacologic treatment for HSDD in premenopausal women approved in the United States. Addyi prescribing information and REMS documentation are available through the FDA. Because of a Risk Evaluation and Mitigation Strategy (REMS) requiring certified prescribers and certified dispensing pharmacies, not every Illinois pharmacy stocks it.

The key BEGONIA trial (N=1,378) published in the Journal of Sexual Medicine in 2014 demonstrated that flibanserin 100 mg nightly increased satisfying sexual events by 0.5 events per 28 days over placebo at 24 weeks (P<0.001) and improved the Female Sexual Function Index desire domain score significantly versus placebo [1]. Those efficacy data formed part of the FDA's basis for approval.

Does Illinois Medicaid Cover Addyi?

Illinois Medicaid covers flibanserin with prior authorization. That means a prescribing clinician must submit clinical documentation showing the patient meets coverage criteria before the pharmacy claim is processed. Typical prior authorization requirements for HSDD medications include a confirmed diagnosis of acquired, generalized HSDD in a premenopausal woman, documented exclusion of contributing medical conditions (thyroid disease, depression, relationship distress), and often a brief trial period or documentation that non-pharmacologic approaches have been considered.

Prior authorization approval timelines through the Illinois Department of Healthcare and Family Services typically run 3 to 14 business days, though urgent requests may be processed faster. Clinicians filing through a certified REMS prescriber account can submit PA paperwork simultaneously with the REMS enrollment, reducing administrative lag.

Illinois Medicaid beneficiaries whose PA is approved pay nothing out of pocket under the standard Medicaid cost-sharing schedule. Those whose PA is denied can appeal using the Illinois Medicaid fair hearing process. The Illinois Department of Healthcare and Family Services publishes its preferred drug list and prior authorization criteria at HFS.illinois.gov, which clinicians should consult for the current cycle criteria. HSDD is classified under ICD-10 code F52.0 (hypoactive sexual desire dysfunction), and accurate coding on the PA form is required for a clean submission.

Research published in JAMA Internal Medicine examined barriers to HSDD treatment access across state Medicaid programs and found that prior authorization requirements varied substantially by state formulary tier placement, underscoring the importance of checking current state-specific criteria rather than relying on national averages [2].

Is Compounded Flibanserin Legal in Illinois?

Compounded flibanserin is legal in Illinois when prepared by a licensed 503A pharmacy operating under state pharmacy board oversight and federal USP Chapter standards. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that compound on a patient-by-patient basis following receipt of a valid prescription from a licensed practitioner [3]. Illinois-licensed 503A pharmacies may compound flibanserin in appropriate dosage forms (typically oral capsules or sublingual preparations) when a practitioner determines a compounded preparation is necessary for an individual patient.

Cost is the primary reason Illinois patients pursue compounded flibanserin. Compounded preparations from 503A pharmacies can reduce monthly cost substantially compared to the $880 branded list price. Some Illinois telehealth platforms partnered with compounding pharmacies offer compounded flibanserin programs with all-inclusive monthly pricing that includes the prescription, compounding, and shipping, sometimes at costs below $100 per month. Pricing varies by pharmacy, formulation, and whether the platform charges a separate consultation fee.

Compounded flibanserin is not FDA-approved. Patients should understand that compounded preparations lack the efficacy and safety data associated with the branded product's clinical trial program. The FDA's guidance on 503A compounding pharmacies clarifies that compounded drugs are not required to demonstrate bioequivalence to branded counterparts [3]. Clinicians prescribing compounded flibanserin in Illinois should document the clinical rationale for compounding in the patient's medical record. The Illinois Department of Financial and Professional Regulation oversees state pharmacy licensure; patients can verify a compounding pharmacy's Illinois license status at IDFPR.illinois.gov.

A 2022 analysis in the journal Menopause examined patient-reported outcomes with off-label and compounded sexual dysfunction treatments and noted that preparation variability across compounding pharmacies was a recognized clinical concern [4]. That finding reinforces the importance of choosing an Illinois-licensed, quality-verified compounding pharmacy rather than an out-of-state mail-order operation that may not hold an Illinois non-resident pharmacy license.

Can Illinois Patients Get Addyi Through Telehealth?

Telehealth prescribing of flibanserin is permitted in Illinois. The Illinois Telehealth Act, substantially updated in 2021, requires that telehealth services meet the same standard of care as in-person visits [5]. A licensed Illinois prescriber conducting a synchronous video visit that includes a thorough sexual and medical history, review of contraindications (alcohol use, CYP2C19 inhibitors, hypotension risk), and appropriate REMS certification can legally prescribe Addyi or write a compounded flibanserin prescription for an Illinois patient without an in-person examination having occurred first, provided the standard of care is met.

REMS certification for prescribers takes roughly 10 to 15 minutes and is completed online through the Addyi REMS portal. Certified pharmacies must also be enrolled. Some large national telehealth platforms serving Illinois patients are pre-enrolled in the REMS system, which means a patient can complete a video visit and have a prescription transmitted to a REMS-certified pharmacy on the same day.

Illinois also requires that telehealth providers have access to the patient's medical history or conduct a sufficient evaluation to prescribe safely, a standard the American College of Obstetricians and Gynecologists (ACOG) has affirmed applies to sexual medicine consultations [6]. Patients using telehealth for flibanserin should prepare a medication list (particularly CYP2C19 inhibitors like fluconazole, which are contraindicated per the FDA label), a menstrual and hormonal history, and any prior HSDD treatment records.

Which Insurance Plans Cover Addyi in Illinois?

Commercial insurance coverage for Addyi in Illinois is inconsistent. Large employer-sponsored plans, individual marketplace plans, and BCBS Illinois, Aetna Illinois, United Healthcare Illinois, and Cigna Illinois networks each make independent formulary decisions. Some plans cover flibanserin at Tier 3 or Tier 4, producing copays of $50 to $200 per month after deductible. Others exclude it entirely as a "lifestyle" medication or require step therapy through off-label treatments first.

The most reliable way for an Illinois patient to determine coverage is to call the member services number on the back of their insurance card and ask specifically whether flibanserin 100 mg (NDC 68712-017-30) is covered, at what tier, and whether prior authorization is required. Having the NDC number ready speeds the lookup.

A study in the Journal of Women's Health examining insurance coverage patterns for women's sexual health medications found that coverage for flibanserin lagged behind comparable male sexual dysfunction treatments on major commercial formularies, a disparity that advocacy groups including the Now Is the Time campaign have documented [7]. The FDA itself noted in its 2015 approval announcement that equitable treatment of female sexual dysfunction in coverage decisions was a recognized policy concern.

Patients whose commercial plans exclude Addyi entirely may find the Sprout savings card more useful than fighting a formulary appeal, depending on the clinical timeline.

How Does the Sprout Pharmaceuticals Savings Card Work in Illinois?

The Sprout Pharmaceuticals Addyi savings card (also called the Addyi co-pay savings program) is available to commercially insured Illinois patients and can reduce the monthly co-pay to as low as $0 for eligible plans. The card does not apply to patients enrolled in federal or state government insurance programs including Medicare, Medicaid, CHIP, TRICARE, or VA benefits.

Enrollment is completed online at the Addyi manufacturer website. Once enrolled, patients present the card at any REMS-certified retail pharmacy in Illinois alongside their insurance card. The savings card acts as secondary insurance and covers the gap between what the plan pays and the patient's cost-share, up to a defined annual maximum (currently $2,400 per calendar year per the manufacturer's published terms, though Illinois patients should verify current terms at the time of enrollment as these figures can change annually).

Cash-pay patients (those without any commercial insurance) do not benefit from the savings card. For those patients, the most practical cost-reduction strategy is a compounded flibanserin prescription through a licensed Illinois 503A pharmacy or an application for the Sprout patient assistance program, which is income-based and may provide medication at no cost for qualifying patients.

The savings card cannot be combined with copay accumulator programs used by some Illinois employer plans. Patients on plans with accumulator adjusters should ask HR or their plan administrator whether accumulators apply before counting on the $0 copay scenario.

What's the Most Affordable Path for Illinois Patients in 2026?

The most affordable path depends on insurance status. The decision framework below reflects current Illinois pricing and legal options:

Pathway 1: Illinois Medicaid with PA approved. Effective monthly cost: $0. Timeline: 3 to 14 business days for PA determination. Best for Medicaid-enrolled patients with a prescriber willing to submit documentation.

Pathway 2: Commercial insurance with Sprout savings card. Effective monthly cost: $0 to $50 for most qualifying plans. Timeline: Same-day at REMS-certified pharmacy once insurance confirms coverage. Best for patients with mid-tier commercial coverage and no accumulator adjuster.

Pathway 3: Compounded flibanserin via licensed Illinois 503A pharmacy. Effective monthly cost: $40 to $120 depending on pharmacy and formulation. Timeline: 3 to 7 days including telehealth consultation. Best for uninsured patients or those whose plans exclude branded Addyi and whose prescribers are comfortable with compounded preparations.

Pathway 4: Branded Addyi cash pay plus GoodRx or similar discount card. Effective monthly cost: $600 to $880. Discount cards rarely produce more than 10 to 15% off the Addyi WAC because it lacks generic competition. This pathway is the least cost-effective for most Illinois patients and should be considered only when pathways 1 through 3 are unavailable.

Prescribers should discuss all four pathways with patients at the point of prescribing, because the access decision is inseparable from the cost decision for a medication at this price point.

Clinical Safety Facts Illinois Prescribers and Patients Must Know

Flibanserin's safety profile includes three FDA-boxed warnings: hypotension and syncope, especially with alcohol; risk with moderate or strong CYP3A4 inhibitors; and risk with strong or moderate CYP2C19 inhibitors [3]. These are not theoretical concerns. The REMS program exists because the alcohol interaction produced clinically significant hypotension and syncope in controlled trials, with blood pressure dropping to levels requiring intervention in some subjects.

The prescriber checklist before initiating flibanserin in any Illinois patient should confirm: premenopausal status, acquired and generalized nature of the desire disorder, absence of alcohol use or willingness to abstain completely, absence of hypotension or syncope history, and a current medication list screened for CYP3A4 and CYP2C19 inhibitors. Common Illinois prescriptions that interact include fluconazole (strong CYP2C19 and moderate CYP3A4 inhibitor), oral contraceptives containing ethinyl estradiol (moderate CYP3A4 inhibitors), and some SSRIs affecting CYP2D6 pathways.

The BEGONIA trial also reported that the most common adverse events with flibanserin 100 mg were dizziness (11.4%), somnolence (11.2%), nausea (10.4%), and fatigue (9.2%), all occurring at rates roughly double placebo [1]. These events were more frequent when flibanserin was taken at times other than bedtime, reinforcing the importance of the bedtime dosing instruction.

A 2016 systematic review in the Annals of Internal Medicine analyzing four key flibanserin trials (combined N=5,914) concluded that the drug produced statistically significant but modest improvements in desire scores and satisfying sexual events, with a number needed to treat of approximately 8 to 14 depending on the outcome measure [8]. That context matters for shared decision-making conversations with Illinois patients weighing an $880 per month commitment against a modest average effect size.

The American College of Obstetricians and Gynecologists' Committee Opinion on female sexual dysfunction states that HSDD is a legitimate medical condition warranting treatment and that flibanserin is an appropriate pharmacologic option for premenopausal patients meeting diagnostic criteria when non-pharmacologic interventions have been insufficient [6]. That guideline language supports the medical necessity arguments used in prior authorization requests for both Illinois Medicaid and commercial payers.

Patients should also be counseled that flibanserin requires 4 to 8 weeks of consistent nightly use before a meaningful clinical response can be assessed. The prescribing information recommends discontinuing the drug if no improvement is noted after 8 weeks. Illinois clinicians writing 30-day prescriptions should build in a follow-up appointment at the 8-week mark to evaluate response before authorizing a third fill.

The endocrine basis of HSDD, involving central dopamine and norepinephrine pathways alongside serotonin modulation, distinguishes flibanserin mechanistically from PDE5 inhibitors used for male erectile dysfunction. Flibanserin acts as an agonist at 5-HT1A receptors and an antagonist at 5-HT2A receptors, shifting the neurochemical balance in the hypothalamic areas regulating sexual motivation [9]. That mechanism explains both its therapeutic effect and its interaction risk with serotonergic drugs.

Research published in Sexual Medicine Reviews has examined the relationship between hormonal status, particularly estrogen and testosterone, and HSDD symptom severity in women approaching perimenopause, noting that flibanserin's premenopausal-only FDA indication means Illinois clinicians must confirm menstrual status carefully before prescribing [10]. Women within 12 months of their last menstrual period who are otherwise healthy may still qualify if their hormonal profile confirms premenopausal status.